Adjusted outcomes: RR from logistic regression
| (1) | (2) | (3) | (4) | (5) | (6) | |
| Month 4 combined prevalence of four STIs tested by NAAT* | Month 8 combined prevalence of four STIs tested by NAAT* | Month 12 combined prevalence of four STIs tested by NAAT* | Month 12 combined measure for three STIs detected by serology at baseline and month 12† | Month 12 combined prevalence of four STIs tested by NAAT* men only | Month 12 combined prevalence of four STIs tested by NAAT* women only | |
| High-value CCT (95% CI) | 0.92 (0.62 to 1.20) | 0.90 (0.61 to 1.18) | 0.73 (0.47 to 0.99) | 1.03 (0.74 to 1.32) | 0.68 (0.25 to 1.10) | 0.76 (0.46 to 1.07) |
| Low-value CCT (95% CI) | 0.94 (0.63 to 1.26) | 0.85 (0.58 to 1.13) | 1.06 (0.75 to 1.38) | 0.82 (0.60 to 1.03) | 1.31 (0.73 to 1.89) | 0.98 (0.63 to 1.33) |
| Number positive | 242 (11.7%) | 258 (12.3%) | 257 (11.6%) | 227 (10.3%) | 98 (9.0%) | 159 (14.2%) |
| N | 2077 | 2092 | 2211 | 2210 | 1093 | 1118 |
Results adjusted for gender, education, age, marital status, income, socioeconomic status, subvillage and baseline STIs.
Robust SEs in parentheses, clustered at both the household and the subvillage levels.
The reference group for the computation of the RRs is the control group.
↵* Chlamydia, gonorrhoea, trichomonas, Mycoplasma genitalium.
↵† HIV, herpes simplex virus 2, syphilis.
CCT, conditional cash transfer; NAAT, nucleic acid amplification test; STI, sexually transmitted infection.